Key Highlights

● LH shares ended 9 October 2026 at $311.99.

● Market data consensus target is $337.73.

● The second data set shows a mean of $344.81 and a median of $352.50.

● Truist raised its target from $350 to $365 on 21 September.

Labcorp (NYSE:LH), a member of the S&P 500, closed at $311.99 on Friday 9 October 2026. The consensus target sits moderately above the share price. Recent broker revisions have mostly been upward.

What Is the Latest Analyst Price Target?

Market data reports a consensus target of $337.73 from 12 ratings in the past 12 months, with a high of $380 and a low of $300. The second data set shows a mean of $344.81, a median of $352.50, a high of $385 and a low of $293, based on a larger group of roughly 17 to 18 analysts.

What Are Wall Street Analysts Saying?

Sentiment is positive overall. Market data records nine Buy ratings, three Hold ratings and no Sell ratings, giving a Moderate Buy consensus. The second data set shows a slightly more mixed picture, with one Sell among 17 analysts.

Recent named broker actions on market data have mostly moved targets higher. Truist Financial raised its target from $350 to $365 on 21 September with a Buy rating. UBS lifted its target from $361 to $380 on 11 September, also with a Buy rating, while Barclays raised its target from $320 to $330 on the same day with an Equal Weight rating. Mizuho set a $355 target on 10 August, and Piper Sandler raised its target from $300 to $309 on 4 August with a Neutral rating.

JPMorgan moved from $330 to $360 on 3 August with an Overweight rating, and Morgan Stanley went from $308 to $338 on 31 July, also Overweight. Deutsche Bank reiterated a Hold rating with a $306 target on 31 July, and Robert W. Baird set a $352 target the same day. Bank of America raised its target from $300 to $320 on 13 July with a Buy rating.

What Could Help the Stock Reach the Price Target?

Market data reports that Labcorp's second-quarter 2026 earnings per share were $4.99 against a consensus of $4.78, with revenue of $3.73 billion against $3.71 billion expected. The company also raised its full-year 2026 earnings per share guidance to a range of $18.10 to $18.55. Continued delivery against that guidance, together with further upward revisions to forecasts, is the most direct route to the shares closing the gap with the consensus target.

What Could Prevent the Stock Reaching the Target?

With the share price already above the low target of $300 and the average target only about 8% higher, the room for upside is moderate rather than large.

Labcorp and the Gap to Analyst Targets

Labcorp closed at $311.99 on 9 October 2026, against a market data consensus target of $337.73. Truist Financial raised its target from $350 to $365 on 21 September with a Buy rating.